Related Experiment Video
Updated: Jun 28, 2026

In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
Deleted in liver cancer 1 controls cell migration through a Dia1-dependent signaling pathway
Gerlinde Holeiter1, Johanna Heering, Patrik Erlmann
1Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany.
Abstract:
Deleted in liver cancer (DLC) 1 and 2 are Rho GTPase-activating proteins that are frequently down-regulated in various types of cancer. Ectopic expression in carcinoma cell lines lacking these proteins has been shown to inhibit cell migration and invasion. However, whether the loss of DLC1 or DLC2 is the cause of aberrant Rho signaling in transformed cells has not been investigated. Here, we have down-regulated DLC1 and DLC2 expression in breast cancer cells using a RNA interference approach. Silencing of DLC1 led to the stabilization of stress fibers and focal adhesions and enhanced cell motility in wound-healing as well as chemotactic Transwell assays. We provide evidence that enhanced migration of cells lacking DLC1 is dependent on the Rho effector protein Dia1 but does not require the activity of Rho kinase. By contrast, DLC2 knockdown failed to affect the migratory behavior of cells, suggesting that the two proteins have distinct functions. This is most likely due to their differential subcellular localizations, with DLC1 found in focal adhesions and DLC2 being mainly cytosolic. Collectively, our data show that DLC1 is critically involved in the control of Rho signaling and actin cytoskeleton remodeling and that its cellular loss is sufficient for the acquisition of a more migratory phenotype of breast cancer cells.
Insights
Loss of Deleted in liver cancer (DLC) 1 in breast cancer cells enhances migration by stabilizing cell structures. DLC1, unlike DLC2, is crucial for controlling Rho signaling and cell movement.
Area of Science:
- Cell Biology
- Cancer Research
- Molecular Biology
Background:
- Deleted in liver cancer (DLC) 1 and 2 are Rho GTPase-activating proteins often downregulated in cancers.
- Previous studies showed ectopic expression inhibits cancer cell migration and invasion.
Purpose of the Study:
- To investigate if DLC1 or DLC2 loss causes aberrant Rho signaling in transformed cells.
- To determine the specific roles of DLC1 and DLC2 in breast cancer cell migration.
Main Methods:
- RNA interference was used to down-regulate DLC1 and DLC2 expression in breast cancer cells.
- Cell motility was assessed using wound-healing and Transwell assays.
- The involvement of Rho effector proteins was analyzed.
Main Results:
- DLC1 silencing stabilized stress fibers and focal adhesions, enhancing cell motility.
- Enhanced migration in DLC1-deficient cells depended on Dia1 but not Rho kinase.
- DLC2 knockdown did not affect cell migration, indicating distinct functions.
Conclusions:
- DLC1 critically controls Rho signaling and actin cytoskeleton remodeling.
- Loss of DLC1 is sufficient to promote a migratory phenotype in breast cancer cells.
- Differential subcellular localization (DLC1 in focal adhesions, DLC2 cytosolic) likely explains distinct functions.
Related Concept Videos
Cancer Cell Migration through Invadopodia
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...

